Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00573508 · ClinicalTrials.gov registry record · Phase 4

Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life

A Phase 4 study, sponsored by Astellas Pharma.

Completed
Registry status
Phase 4
Development phase
768
Enrollment target

NCT00573508 is a Phase 4 study that has completed, run by Astellas Pharma. The registered enrollment target is 768 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00573508, a Phase 4 study, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 4
Development phase
768 participants
Enrollment target

Study Summary

Evaluate the effect of VESIcare® on symptom bother for subjects with OAB

Interventions

  • DRUG Placebo
  • DRUG Solifenacin Succinate

Trial Details

FieldValue
Enrollment Target 768 participants
Start Date 2007-08
Est. Completion 2008-07
Phase Phase 4

Sponsor

Astellas Pharma

165 total trials

What the Registry Record Tells You About NCT00573508

The ClinicalTrials.gov registry entry for NCT00573508 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 768 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00573508 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00573508 about?

NCT00573508 is a clinical study titled "Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life". Evaluate the effect of VESIcare® on symptom bother for subjects with OAB

What is the current status of trial NCT00573508?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 768 participants. The study started on 2007-08. Estimated completion is 2008-07.

What interventions are being tested in trial NCT00573508?

The interventions under investigation include: Placebo (DRUG), Solifenacin Succinate (DRUG).

Who is sponsoring clinical trial NCT00573508?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.